Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor–Positive, <i>ERBB2</i>-Negative Metastatic Breast CancerElisabetta Munzone, L. J. Blacher, Carmelo Bengala et al.|JAMA Oncology|2023Cited by 37
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trialValentina Guarneri, PierFranco Conte, Carlo Alberto Giorgi et al.|European Journal of Cancer|2021Cited by 13
NIVES study: A phase II trial of nivolumab (NIVO) plus stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC).Cristina Masini, Carmine Pinto, Cinzia Iotti et al.|Journal of Clinical Oncology|2018Cited by 5
Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database.Edoardo Francini, Daniel Yick Chin Heng, Francesca Montagnani et al.|Journal of Clinical Oncology|2020Cited by 1
Efficacy of bone resorption inhibitors (BRI) + abiraterone acetate + prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry.Edoardo Francini, Daniel Yick Chin Heng, Francesca Montagnani et al.|Journal of Clinical Oncology|2019Cited by 0